¾Å¾ÅÉ«Ó°Ôº

Candidate malaria vaccine provides lasting protection in NIH-sponsored trials

Approach could have role in preventing malaria in pregnancy.

Immunotherapy approach shows potential in some people with metastatic solid tumor

NIH researchers achieved tumor shrinkage in three of seven patients with colorectal cancers.

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

Combination therapy developed by NIH researchers demonstrates the power of precision medicine.

NIH-funded clinical trial links frequent anger to increased risk of heart disease

Findings demonstrate impairment of blood vessel function; may lead to heart attack, stroke.

Hearing aids slow cognitive decline in people at high risk

Hearing aids cut the rate of cognitive decline by nearly half in older adults at high risk of dementia.

NIH clinical trial of tuberculous meningitis drug regimen begins

Six-month multidrug regimen being evaluated against standard treatment.

For people with advanced bladder cancer, combining enfortumab (Padcev) and pembrolizumab (Keytruda) should be the new standard initial treatment, new clinical trial results suggest.

The CAR T-cell therapy axicabtagene ciloleucel (Yescarta) improved survival for people with large B-cell lymphoma that was not responding to initial treatment or had relapsed quickly, according to new data from the ZUMA-7 trial

NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.

NIH study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis

Patients treated with interferon alfa-2b lived for decades after diagnosis in Phase 2 trial.